SIL1

Across TCGA pan-cancer cohorts, SIL1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SIL1 data layer compared with 20 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SIL1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SIL1 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, LSCC, and GBM are the cancer types where SIL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.348	0.812	<.001	48	view →
LSCC	OS	Quartile	II,III,IV	0.585	1.000	.001	14	view →
GBM	DFS	Tertile	All	0.250	0.507	.002	11	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	10	view →
HNSC	DFS	Quartile	All	0.743	0.913	.022	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SIL1–CCRCC (DFS)

Open the CCRCC breakdown →